394 related articles for article (PubMed ID: 22851600)
1. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Pratley RE; Nauck MA; Bailey T; Montanya E; Filetti S; Garber AJ; Thomsen AB; Furber S; Davies M;
Diabetes Care; 2012 Oct; 35(10):1986-93. PubMed ID: 22851600
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
3. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
9. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Davies M; Pratley R; Hammer M; Thomsen AB; Cuddihy R
Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
[TBL] [Abstract][Full Text] [Related]
15. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Langer J; Hunt B; Valentine WJ
J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Zerilli T; Pyon EY
Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]